Microbio (Shanghai) Co. Ltd. has synthesized glucagon-like peptide 1 receptor (GLP1R) agonists reported to be useful for the treatment of obesity, type 2 diabetes and nonalcoholic fatty liver disease.
With an eye toward the future, the U.S. Patent and Trademark Office (USPTO) is seeking comment on artificial intelligence (AI) technologies and inventorship issues that may arise as AI takes on a bigger role in innovation.
With China taking steps to enact or propose amendments to more than 60 intellectual property (IP)-related laws and regulations over the past few years, drug and device companies doing business in the country need to keep abreast of the changes. Despite China’s efforts, most of the participants in the Feb. 9 U.S. Patent and Trademark Office’s quarterly China IP webinar indicated in a pre-webinar survey that they have yet to see much of an improvement in China’s enforcement and regulation of IP rights.
Lateral Pharma Pty. Ltd. has discovered peptides targeting LanC-like (LANCL) proteins reported to be useful for the treatment of diabetes, infections, inflammation, obesity, pain, metabolic, muscle and neurological disorders, among others.
Shanghai Allist Pharmaceuticals Co. Ltd. has discovered pyridopyrimidines acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has divulged amide compounds acting as epidermal growth factor receptor (EGFR) mutant inhibitors reported to be useful for the treatment of cancer.
Alephoson Biopharmaceuticals Ltd. has disclosed peptide-drug conjugates comprising a cell-penetrating peptide covalently linked to melphalan that are reported to be useful for the treatment of retinoblastoma.
With an eye toward the future, the U.S. Patent and Trademark Office (USPTO) is seeking comment on artificial intelligence (AI) technologies and inventorship issues that may arise as AI takes on a bigger role in innovation.
RSS
